Regeneron revenue advances to $4.29B as growth accelerates
Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter 2026 total revenue of $4.29 billion, up 17% year over year, supported by higher collaboration revenue and product sales growth.










